@article{IR,
      recid = {43675},
      author = {Streblow, Zachary and Haese, Nicole N. and Streblow,  Zachary J. and Garazan, Atefeh and Andoh, Takeshi and  Bonin, Kiley and Streblow, Cassilyn E. and Denton, Michael  and Medica, Samuel and Streblow, Gabriel J. and Kreklywich,  Craig N. and Heise, Mark and Morrison, Thomas E. and Patek,  Ashish and Streblow, Daniel N.},
      title = {2-pyrimidone compound series prevents acute viremia and  chronic chikungunya virus disease in a mouse model of  infection},
      publisher = {Oregon Health and Science University},
      address = {2024},
      number = {IR},
      abstract = {Alphaviruses are arthropod-transmitted RNA viruses,  including the NIAID Category B priority pathogens Eastern  equine encephalitis (EEEV), Venezuelan equine encephalitis  (VEEV) and chikungunya (CHIKV) viruses. In November of  2023, the first chikungunya virus vaccine became FDA  approved for use in individuals 18 years of age and older  who are at increased risk of exposure to CHIKV, although no  FDA-licensed antiviral therapeutics are available to treat  alphavirus infection or disease, thus demonstrating a need  in the field of public health. We identified a small  molecule antiviral hit using a screen against CHIKV.},
      url = {http://digitalcollections.ohsu.edu/record/43675},
      doi = {https://doi.org/10.6083/bpxhc43675},
}